EGFR and neoplasm: We have shown earlier that CAFs increase resistance to cetuximab treatment (a monoclonal antibody against EGFR; Erbitux®, Merck KGaA) and increase the MMP1 expression of HNSCC cells during co-culturing compared with tumor cells grown alone in a 2D model [9].